BLFS is growing its business while keeping high growth as the regenerative medicine market opportunity develops.” BLFS hold the leading supplier position for pre-formulated, clinical grade bio-preservation media products. We estimate that our HypoThermosol^® cell/tissue storage medium and CryoStor^® cryopreservation freeze media products are used in more than 50 clinical trial-stage cell and tissue based therapies in the regenerative medicine field; any 1 of which could generate $1 M per year in revenue, if regulatory and marketing approvals are obtained by our customers. BLFS closed at $0.29 on no volume on Thursday, 3/29/13. As traders stayed silent post seeking profit and always seems to pop back. I am still … optimistic about BLFS, now that Q4 and FY12 results are out – my expectations are on target – yet again as BLFS focuses another “rebound” play! The 50 day moving average is up to $0.30 and the 200 day average is up $0.28. The float is only 19.02 M as compared to outstanding shares of 69.67 M. I continue to reiterate this as a “STRONG BUY”
As positive as I am about the BLFS future, the fact remains that BLFS is still unprofitable. Until BLFS starts to be profitable I don't see how there will be any significant upside movement. In sum, unprofitability is still a major problem for BLFS.